Suchergebnisse - "Meyer, Antoine"

PubPharm (9)

1

Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2024

von Meyer, A. | Miranda, S. | Drouin, J. | +3

2

Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease : A GETAID multicentre cohort study

enthalten in: Alimentary pharmacology & therapeutics | 2023

von Fumery, M. | Defrance, A. | Roblin, X. | +22

CommentIn: Aliment Pharmacol Ther. 2023 Apr;57(8):909-910. - PMID 36952268

3

Editorial : ustekinumab during pregnancy - reassuring but still not enough

enthalten in: Alimentary pharmacology & therapeutics | 2023

von Amiot, A. | Meyer, A. | Carbonnel, F.

CommentOn: Aliment Pharmacol Ther. 2022 Aug;56(3):477-490. - PMID 35560249

4

Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis : a GETAID multicentre cohort study

enthalten in: Scandinavian journal of gastroenterology | 2022

von Meyer, A. | Fumery, M. | Peyrin-Biroulet, L. | +22

5

Systematic review with meta-analysis : the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor

enthalten in: Alimentary pharmacology & therapeutics | 2022

von Parrot, L. | Dong, C. | Carbonnel, F. | +1

6

Vedolizumab Clinical Decision Support Tool Predicts Efficacy of Vedolizumab But Not Ustekinumab in Refractory Crohn's Disease

enthalten in: Inflammatory bowel diseases | 2022

von Alric, H. | Amiot, A. | Kirchgesner, J. | +6

7

The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2020

von Kassouri, L. | Amiot, A. | Kirchgesner, J. | +6

8

Letter : choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail. Authors' reply

enthalten in: Alimentary pharmacology & therapeutics | 2020

von Alric, H. | Amiot, A. | Carbonnel, F. | +1

CommentOn: Aliment Pharmacol Ther. 2020 Apr;51(8):789-800. - PMID 32133656

9

The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor

enthalten in: Alimentary pharmacology & therapeutics | 2020

von Alric, H. | Amiot, A. | Kirchgesner, J. | +6

CommentIn: Aliment Pharmacol Ther. 2020 Aug;52(3):561-562. - PMID 32656826

1
[1]